KIT and neoplasm: In the tumour cells, cabozantinib interrupts VEGFR1/VEGFR2/c-KIT/TIE2 pathways [47], downregulating angiogenic factors (HIF1α, VEGFA) [48] and vascular remodelling factors (MMP2, MMP9) [49].